Opioid Addiction

Featured Article

The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists

The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists

The guideline formulated by the Centers for Disease Control and Prevention in an effort to curb opioid overdose-related deaths included a recommendation for steep reductions in opioid doses for patients taking high doses of the drug for chronic pain.

Latest

More Than Two-Thirds of Drug OD Deaths in 2017 Involved Opioids

More Than Two-Thirds of Drug OD Deaths in 2017 Involved Opioids

More than two-thirds of drug overdose deaths in 2017 involved an opioid, with increases in overdose deaths from all opioids and synthetic opioids seen from 2016 to 2017.

Reviewing the Use of Buprenorphine in Perioperative Pain Management

Reviewing the Use of Buprenorphine in Perioperative Pain Management

The perioperative use of µ-opioid agonists and continuation of buprenorphine treatment in patients on buprenorphine therapy were found to be safe for the management of postsurgical pain.

Smaller Heads Related to Opioid-Related Neonatal Abstinence Syndrome

Smaller Heads Related to Opioid-Related Neonatal Abstinence Syndrome

Chronic opioid use during pregnancy that causes neonatal abstinence syndrome (NAS) is associated with smaller neonatal head circumference.

Prevalence of Benzodiazepine Use, Misuse Among US Adults Analyzed

Prevalence of Benzodiazepine Use, Misuse Among US Adults Analyzed

Alprazolam was found to be the most commonly misused benzodiazepine.

Dental Procedure-Related Opioid Exposure and Later Risk for Opioid Abuse

Dental Procedure-Related Opioid Exposure and Later Risk for Opioid Abuse

A substantial proportion of adolescent and young adults receiving opioids for dental procedures may be at higher risk for later opioid use and abuse.

reSET-O Digital Therapeutic for Opioid Use Disorder Now Available

reSET-O Digital Therapeutic for Opioid Use Disorder Now Available

Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care.

Nonmedical Prescription Opioid Use Motivated by Pain Relief in Adolescence Predicts Later SUD

Nonmedical Prescription Opioid Use Motivated by Pain Relief in Adolescence Predicts Later SUD

A set of characteristics of nonmedical use of prescription opioids in adolescents may help identify youth at high risk for substance use disorder, including opioid misuse, in early midlife.

A Case for Ministerial Recall of High-Strength Opioids in Canada

A Case for Ministerial Recall of High-Strength Opioids in Canada

The Protecting Canadians from Unsafe Drugs Act passed into law in 2014 empowered the minister of health to recall a drug if they "believe that a therapeutic product presents a serious or imminent risk of injury to health."

HIV Patients Misusing Opioids Have Poorer Health Outcomes

HIV Patients Misusing Opioids Have Poorer Health Outcomes

Researchers found substantial room for improvement in the delivery of substance use and mental health counseling and treatment and HIV/STD prevention counseling.

Increase Seen in Amphetamine, Opioid Use in Pregnant Women

Increase Seen in Amphetamine, Opioid Use in Pregnant Women

The incidence of amphetamine and opioid use has increased among pregnant women, especially in rural counties.

CDC: Top 10 Drugs Involved in Drug Overdose Deaths

CDC: Top 10 Drugs Involved in Drug Overdose Deaths

Using data from the 2011 to 2016 National Vital Statistics System-Mortality files, the authors conducted a literal text analysis of death certificates to identify drugs mentioned as contributing to the cause of overdose death.

Monthly Injections of Naltrexone, Opioid Antagonist, Superior to Oral Design

Monthly Injections of Naltrexone, Opioid Antagonist, Superior to Oral Design

Heroin addicts were more compliant with taking monthly injections of naltrexone rather than consuming it in a pill version.

Additional Naloxone Formulation Submitted to FDA for Review

Additional Naloxone Formulation Submitted to FDA for Review

Currently, naloxone is supplied in ampules and vials for IV, IM or SC administration, in a prefilled auto-injector, and as a nasal spray.

Opioid Use Disorder Associated With Greater Complications After Cardiac Surgery

Opioid Use Disorder Associated With Greater Complications After Cardiac Surgery

Among patients undergoing cardiac surgery, those with vs without opioid use disorder may have higher rates of complications and encounter greater costs.

Brixadi Gets Tentative FDA Approval for Opioid Use Disorder

Brixadi Gets Tentative FDA Approval for Opioid Use Disorder

Brixadi utilizes FluidCrystal Injection Depot Technology; once in contact with fluids in the tissue, the solution turns into a nanostructured liquid-crystalline gel allowing for slow release of buprenorphine at a steady rate over 1 week or 1 month.

Addiction Medicine Consultation Improves Antibiotic Compliance in Patients With Opioid Use Disorders

Addiction Medicine Consultation Improves Antibiotic Compliance in Patients With Opioid Use Disorders

Patients with opioid use disorders who required hospitalization with lengthy antibiotic therapy had better outcomes with addiction medicine consultation.

Pregnancy-Associated Mortality Involving Opioids Up

Pregnancy-Associated Mortality Involving Opioids Up

From 2007 to 2016, there was a sharp increase in pregnancy-associated mortality involving opioids.

Evzio Authorized Generic Soon to Be Available

Evzio Authorized Generic Soon to Be Available

In addition to the new authorized generic, Evzio is now available at $178 per carton (2 auto-injectors per carton) for government agencies, first responders, health departments, and other qualifying groups when they purchase directly from kaléo or authorized distributors.

Prescription Digital Therapeutic Approved for Opioid Use Disorder

Prescription Digital Therapeutic Approved for Opioid Use Disorder

reSET-O is intended for use as an adjunct to outpatient treatment that includes transmucosal buprenorphine (medication-assisted-treatment [MAT]) and contingency management for patients aged ≥18 years who are currently under clinician supervision.

FDA Warns Two Companies About Bogus Opioid Addiction Treatment

FDA Warns Two Companies About Bogus Opioid Addiction Treatment

Warning letters about products illegally marketed as treatments for opioid addiction, pain, and anxiety have been sent to two companies from the FDA.